Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Common Equity (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Common Equity for 4 consecutive years, with $88.3 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 54.86% to $88.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $88.3 million through Dec 2025, up 54.86% year-over-year, with the annual reading at $88.3 million for FY2025, 54.86% up from the prior year.
  • Common Equity hit $88.3 million in Q4 2025 for Axsome Therapeutics, up from $73.7 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $278.8 million in Q2 2023 to a low of $14.7 million in Q1 2022.
  • Historically, Common Equity has averaged $114.6 million across 4 years, with a median of $97.9 million in 2024.
  • Biggest five-year swings in Common Equity: soared 1734.36% in 2023 and later crashed 70.15% in 2024.
  • Year by year, Common Equity stood at $109.6 million in 2022, then surged by 74.32% to $191.0 million in 2023, then plummeted by 70.15% to $57.0 million in 2024, then surged by 54.86% to $88.3 million in 2025.
  • Business Quant data shows Common Equity for AXSM at $88.3 million in Q4 2025, $73.7 million in Q3 2025, and $73.1 million in Q2 2025.